ABCA7 loss of function and Alzheimer's disease
Official title: Neuronal ABCA7 loss of function and Alzheimer’s disease
Funded at Mayo Clinic Jacksonville · NIH-11463253 · Data updated 2026-11-12
This grant examines how changes in ABCA7, a brain lipid transporter, may influence Alzheimer's disease risk and progression in people.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Jacksonville NIH-funded |
| Lab location | 1 site (Jacksonville, United States) |
| Project start | June 1, 2023 |
| Project end | May 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $686,761 |
| NIH project number | 4R01AG081203-02 |
| Project ID | NIH-11463253 on NIH RePORTER |
Who could benefit from this research
✓Could help
Individuals with Alzheimer's disease or those at risk due to ABCA7-related genetic variants may benefit from advances arising from this research.
✕Less likely to help
People without ABCA7-related risk factors or without Alzheimer's pathology may have limited direct benefit from these findings.
What this research studies
Researchers are studying how ABCA7 gene changes affect lipid distribution and mitochondrial function in neurons using human iPSC-derived neurons and brain-like models. By looking at how ABCA7 loss alters lipid pathways and neuronal energy, they aim to identify how these changes contribute to Alzheimer’s disease. The work combines genetic data, cell models, and analysis of brain pathways to uncover central disease mechanisms. If successful, this could point to new targets to slow or prevent disease progression.
Why it matters
Potential benefit: Understanding ABCA7's role could lead to new strategies to prevent or slow Alzheimer's by targeting lipid metabolism in brain cells.
How similar studies have gone: Previous studies have linked ABCA7 and lipid metabolism to Alzheimer’s risk, with emerging evidence supporting a mechanistic link.
Where this research is happening
-
Mayo Clinic Jacksonville
Jacksonville, United States Active
Researchers
- Principal investigator: Kanekiyo, Takahisa — Mayo Clinic Jacksonville
- Study coordinator: Kanekiyo, Takahisa
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.